Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 29

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 29
---
 could cause actual results,
developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others,
those factors referred to in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is incorporated by reference
herein.

These statements are only current predictions and
are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels
of activity, performance, or achievements to be materially different from those anticipated by the forward-looking statements. We discuss
many of these risks in the documents incorporated by reference herein. You should not rely upon forward-looking statements as predictions
of future events.

Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new
information, future events or otherwise, after the date of this prospectus.

<div align='center'>iii

PROSPECTUS SUMMARY</div>

This summary highlights certain information about us and selected information contained in the prospectus. This summary is not complete and does not contain all of the information that may be important to you. For a more complete understanding of the Company, we encourage you to read and consider the more detailed information included or incorporated by reference in this prospectus and our most recent consolidated financial statements and related notes.

We are a clinical-stage immunology company focused
on developing drugs that may reprogram the patient’s innate immune system to treat disease. We believe this may be done by targeting
cells of the innate immune system that cause acute and chronic inflammation and are involved in immune dysfunction associated with chronic
diseases such as cancer and neurodegenerative diseases. The Company’s drugs are in clinical trials and have not been approved by
a regulatory authority. The Company has two therapeutic platforms – a dominant-negative TNF platform (“DN-TNF”, “XPro™”,
“XPro1595™” or “pegipanermin”) and a Natural Killer (“NK”, or “INKmune™”)
platform. The DN-TNF platform neutralizes soluble TNF (“sTNF”) without affecting trans-membrane TNF (“tmTNF”)
or TNF receptors -TNFR1 and TNFR2. This unique biologic mechanism differentiates the DN-TNF drugs from